IL17RB and ovarian carcinoma: Utilizing drug screening data across a panel of 46 cancer cell lines from 11 tumor lineages, we identified an ovarian cancer‐specific sensitivity to the first‐in‐class CRL4 inhibitors KH‐4‐43 and 33‐11.